Key facts: AstraZeneca's Koselugo gains FDA approval; stock rises 1.4%

TradingView
2025.11.21 01:03
portai
I'm PortAI, I can summarize articles.

AstraZeneca's Alexion unit gained FDA approval for Koselugo, now treating adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas, boosting its market presence.123AstraZeneca's stock rose by 1% following the approval of its drug aimed at controlling the growth of non-cancerous tumors in the U.S., with an additional 0.4% increase noted in subsequent trading.4

  • AstraZeneca's Alexion unit gained FDA approval for Koselugo, now treating adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas, boosting its market presence.123
  • AstraZeneca's stock rose by 1% following the approval of its drug aimed at controlling the growth of non-cancerous tumors in the U.S., with an additional 0.4% increase noted in subsequent trading.4
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.